ArticleFrontiers in oncology2025
Clinical characteristics and treatment outcomes of cervical high-grade squamous intraepithelial lesions in women under 25 years: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rewired DDR-TGF-β-β-catenin-PD-L1 axis accelerates progression and shapes therapy in human papillomavirus-driven cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Limited data are available regarding the clinical characteristics and treatment outcomes of cervical HSIL in women under 25, particularly in Asian populations. This study aimed to investigate the clinical features of cervical HSIL in women under 25 and to compare the efficacy of various treatment modalities, with the goal of informing early detection and optimal management strategies. Methods: A retrospective cohort study was conducted involving 210 patients under 25 who were diagnosed with cervical HSIL at Obstetrics and Gynecology Hospital of Fudan University between January 2019 and December 2021. Data on clinical features, cytology, HPV status, colposcopy findings, and treatment approaches were collected and analyzed. Treatment outcomes were assessed by comparing postoperative cytology, HPV clearance, and pathological results at 6 and 12 months among patients managed with observation, CO2 laser therapy, or LEEP. Results: Most patients (89.0%) were diagnosed via routine screening and 86.7% were asymptomatic. Among symptomatic cases, postcoital bleeding (10.0%) and abnormal vaginal discharge (3.3%) were reported. Cytology showed NILM in 38.1%, ASCUS 30.5%, LSIL 21.0%, HSIL 7.1%, and ASC-H 3.3%. HPV was detected in 98.1% of patients, predominantly HPV16 (65.2%). Cytology alone showed low sensitivity for detecting cervical HSIL (7.1%) compared with HPV testing (98.1%) or co-testing (98.6%, χ²=534.468, P<0.001). At 12-month follow-up, the LEEP group exhibited the highest rates of normal cytology (90.5%), HPV clearance (87.5%), and histologic cure (95.2%), outperforming both the laser and observation groups. Multivariate logistic regression analyses identified reproductive tract inflammation as an independent risk factor for persistent high-risk HPV infection among patients undergoing observation. Conclusions: Most cervical HSIL under 25 are asymptomatic. Cytology alone is insufficient for reliable detection, HPV based screening significantly improves sensitivity. Among treatment strategies, LEEP offers the most effective histological cure rate, although potential reproductive risks warrant careful consideration in nulliparous women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.